LSTA Lisata Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LSTA

Price (delayed)

$2.77

Market cap

$23.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.58

Enterprise value

$418,589

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely ...

Highlights
The net income has soared by 62% YoY and by 2.9% from the previous quarter
The EPS has plunged by 132% from the previous quarter but it has soared by 75% YoY
Lisata Therapeutics's quick ratio has decreased by 29% YoY and by 28% from the previous quarter
LSTA's equity is down by 28% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.caladrius.com
Peers: OMER OMGA

Key stats

What are the main financial stats of LSTA
Market
Shares outstanding
8.31M
Market cap
$23.01M
Enterprise value
$418,589
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$23.17M
EBITDA
-$22.98M
Free cash flow
-$20.03M
Per share
EPS
-$2.58
Free cash flow per share
-$2.48
Book value per share
$5.92
Revenue per share
$0
TBVPS
$6.74
Balance sheet
Total assets
$54.69M
Total liabilities
$6.8M
Debt
$0
Equity
$48.15M
Working capital
$47.33M
Liquidity
Debt to equity
0
Current ratio
8.18
Quick ratio
7.67
Net debt/EBITDA
0.98
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.5%
Return on equity
-37.9%
Return on invested capital
-82.7%
Return on capital employed
-48.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LSTA stock price

How has the Lisata Therapeutics stock price performed over time
Intraday
-1.42%
1 week
-1.07%
1 month
-9.18%
1 year
-14.77%
YTD
1.47%
QTD
-11.22%

Financial performance

How have Lisata Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.71M
Net income
-$20.84M
Gross margin
N/A
Net margin
N/A
The net income has soared by 62% YoY and by 2.9% from the previous quarter
LSTA's operating income has surged by 55% year-on-year

Growth

What is Lisata Therapeutics's growth rate over time

Valuation

What is Lisata Therapeutics stock price valuation
P/E
N/A
P/B
0.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 132% from the previous quarter but it has soared by 75% YoY
LSTA's price to book (P/B) is 33% lower than its 5-year quarterly average of 0.7 but 18% higher than its last 4 quarters average of 0.4
LSTA's equity is down by 28% YoY and by 9% from the previous quarter

Efficiency

How efficient is Lisata Therapeutics business performance
Lisata Therapeutics's return on assets has increased by 48% YoY but it has decreased by 4.5% QoQ
LSTA's ROE is up by 46% YoY but it is down by 5% from the previous quarter
The return on invested capital has increased by 27% year-on-year but it has declined by 5% since the previous quarter

Dividends

What is LSTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LSTA.

Financial health

How did Lisata Therapeutics financials performed over time
Lisata Therapeutics's quick ratio has decreased by 29% YoY and by 28% from the previous quarter
LSTA's current ratio is down by 27% YoY and by 27% QoQ
The debt is 100% less than the equity
LSTA's equity is down by 28% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.